Promoter holding
64.27%
JG
Jubilant Generics Limited - Due diligence report
A 360° intelligence report on Jubl: trust score, financial health, credit view, compliance, directors, growth and distress signals - generat…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Jubl — 360° Intelligence Report
Generated from MCA filings & public records70/100
Trust Score
Moderate
Jubl is assessed as Moderate with a Trust Score of 70/100. Jubl is an active public limited foreign company incorporated in india incorporated in 2013, operating in the Pharma sector. Reported revenue has declined across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and high financial risk profile.
Report generated on 16 Jul 2026 from the latest processed filings. Jubilant Generics Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreModerate
70/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
72/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
45/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
55/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
85/100
Board strength, DIN status, churn and network.
Growth ScoreCaution Indicated
40/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
60/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 55/100 Moderate
- Negative operating earnings - debt service depends on external support.
- Moderate gearing (D/E 38%).
- Externally credit-rated (AA+).
Charges position: 1 open (500.00 cr) · 7 satisfied (810.00 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Others | 1 | 48.0 cr |
| Il & Fs Trust Company Limited | 2 | 48.0 cr |
| Yes Bank Limited | 1 | 48.0 cr |
| Indusind Bank Ltd. | 1 | 48.0 cr |
| Ing Vysya Bank Limited | 1 | 48.0 cr |
| The Ratnakar Bank Limited | 1 | 48.0 cr |
Compliance Score: 72/100 Moderate
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Litigation present in 3 court forum(s).
- Delayed payments to MSME suppliers disclosed (450 disclosure(s)).
- 12 active GST registration(s).
Legal cases on record (3)
05
Director Intelligence
Stability score: 85/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| GAYATRI TARAGI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| JAIDEV SANJEEV RAJPAL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| JAIDEV SANJEEV RAJPAL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SHIRISH GUNDOPANT BELAPURE | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Shikha Aggarwal | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 5 directors on the board.
- No disqualified or deactivated DINs.
- 2 director exit(s) in the last 3 years.
Director & KMP remuneration (FY 2022)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2022 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Jubilant Pharma Limited
Subsidiaries
-
Group entities
-
Capital events
5 allotment(s) · 3 transfer(s)
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Jubilant Pharma Limited | Holding Company | 74.00% |
| Jubilant Pharma Nv | Subsidiary Company | 74.00% |
| Jubilant Pharmaceuticals Nv | Subsidiary Company | 74.00% |
| Psi Supply Nv | Subsidiary Company | 74.00% |
| Jubilant Pharmova Limited | Holding Company | 74.00% |
Key managerial personnel: JAIDEV SANJEEV RAJPAL (CEO) · JAIDEV SANJEEV RAJPAL (Managing Director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 40 · Distress 60
Growth signals & trust indicators
Operating for 12+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Losses deepening year-on-year.
1 open charge(s) registered - assets are encumbered.
MSME payment delays disclosed - latest outstanding 9.77 cr.
3 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence68/100
Review suggested
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- 2 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment56/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 1 open charge(s) of 500.00 cr already registered.
- Compliance record supports lending.
Investor view49/100
Mixed indicators
Growth quality and scalability through an investor lens.
- No clear growth signals in the filed years.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events28 Aug 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
29 Sep 2024
Director ceased
GAYATRI TARAGI
Director ceased
SHIRISH GUNDOPANT BELAPURE
01 Aug 2024
Director appointed
Shikha Aggarwal (Cfo)
20 Jun 2024
Director appointed
SHIRISH GUNDOPANT BELAPURE (Director)
21 May 2024
Director appointed
GAYATRI TARAGI (Director)
11 Oct 2022
Director appointed
JAIDEV SANJEEV RAJPAL (CEO)
Director appointed
JAIDEV SANJEEV RAJPAL (Managing Director)
Director ceased
JAIDEV SANJEEV RAJPAL
30 Jun 2022
Director ceased
RAMAMURTHI KUMAR
31 Mar 2022
Share transfer (FY 2022)
1.00000000 shares to Sanjay Das
Share transfer (FY 2022)
1.00000000 shares to Anuj Jain
Director ceased
ANANT PANDE
30 Sep 2021
Director ceased
ARVIND CHOKHANY
10
Key Observations
Auto-generated from the data aboveRevenue declined 1.42 over the last 4 financial year(s).
Net profit margin moved from 2.1x to 24%.
Debt-to-equity stands at 0.86 - manageable leverage.
Net worth is positive.
5 active director(s) / partner(s); board looks stable and experienced.
12 active GST registration(s) indicate ongoing business operations.
Carries an external credit rating of AA+ from Indiarating.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2022 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 5 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Vital Laboratories | U24100MH1998PTC113058 | Mumbai, Maharashtra, India |
| Aagya Biotech | U74999UR2016PTC007216 | Roorkee, Uttarakhand, India |
| Bharathi Consumer Care Products Private Limited | U24110AP2009PTC064675 | Guntur, Andhra Pradesh, India |
| Balaji | U24116GJ2002PTC040401 | Sanand, Gujarat, India |
| Shodhana | U24230TG2000PTC035348 | Hyderabad, Telangana, India |
| Olon | U24100MH2018FTC314115 | Thane, Maharashtra, India |
| Amrita Enterprises Private Limited | U74999PY2003PTC001704 | Puducherry, Pondicherry, India |
| Teva Pharmaceutical Industries | U33111MH2000FTC326700 | Mumbai, Maharashtra, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Jubl before audits and certifications: compliance score 72/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Jubl: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 55/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Mixed indicators. Growth score 40/100, margin trends, ownership structure and peer set for Jubl - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Review suggested. Trust score 70/100, distress signals and MSME payment-delay disclosures - know whether Jubl pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (3 case(s) on record), regulatory flags, charge documents trail and director networks for Jubl - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Jubl an active company?
Jubl has MCA status “Active” with a compliance score of 72/100 (Moderate).
Is Jubl financially healthy?
Jubl has a Financial Health Score of 45/100 (Caution Indicated) based on its filed financial statements.
Should I do business with Jubl?
Its overall Trust Score is 70/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Jubl?
The ultimate holding entity is Jubilant Pharma Limited. 5 active director(s) are on record.
Does Jubl have loans or charges against its assets?
1 open charge(s) are registered against its assets, and 7 earlier charge(s) stand satisfied.
Is Jubl up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 72/100 (Moderate).
Is it risky to lend to Jubl?
Its Credit Risk Score is 55/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
